Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions

• New RSV prevention products can substantially reduce disease burden. • Longer-actingmonoclonal antibodies, priced affordably, are likely cost-effective. • Maternal vaccines meeting preferred product characteristicswould be cost-effective. • RSV prevention productscanprovide good valuein low-income...
Full description

Saved in:
Author:

Laufer, Rachel S.

Driscoll, Amanda J.

Baral, Ranju

Buchwald, Andrea G.

Campbell, James D.

Coulibaly, Flanon

Diallo, Fatoumata

Doumbia, Moussa

Galvani, Alison P.

Haidara, Fadima C.

Kotloff, Karen L.

Keita, Adama M.

Neuzil, Kathleen M.

Orenstein, Evan W.

Orenstein, Lauren A.V.

Pecenka, Clint

Sow, Samba

Tapia, Milagritos D.

Ortiz, Justin R.

Fitzpatrick, Meagan C.

Format:

Electronic Article

Language:

English

Physical Description:

Online-Ressource

Containing Work:

In: Vaccine - Amsterdam : Elsevier, Vol. 39, No. 35 (2021), p. 5037-5045

Links:

Volltext

DOI / URN:

10.1016/j.vaccine.2021.06.086

Catalog id:

ELV050638734

Haven't found what you're looking for?

Contact us!